Shares of Innate Pharma S.A. (NASDAQ:IPHA – Get Free Report) shot up 1.5% during mid-day trading on Friday . The company traded as high as $1.99 and last traded at $1.97. 4,306 shares traded hands during trading, a decline of 98% from the average session volume of 183,983 shares. The stock had previously closed at $1.94.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and issued a $11.50 price target on shares of Innate Pharma in a research note on Friday, March 28th.
Check Out Our Latest Analysis on IPHA
Innate Pharma Stock Up 1.5 %
About Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Featured Articles
- Five stocks we like better than Innate Pharma
- Stock Market Upgrades: What Are They?
- J.B. Hunt Transport Overcorrects Into a Buying Opportunity
- Financial Services Stocks Investing
- AppLovin: Can Record Profits Overcome Market Skepticism?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- MarketBeat Week in Review – 04/14 – 04/18
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.